Autres langues Gilead Sciences, Inc.

Actions

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Pré-ouverture 14:25:49
65,42 ^USD	+0,23%		64,44	-1,51%

26/04	GILEAD SCIENCES, INC. : TD Cowen toujours à l'achat	ZM
26/04	GILEAD SCIENCES, INC. : Jefferies & Co. à l'achat	ZM

Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy	26/04
Well, it isn't as bad as feared...	26/04
STATI UNITI. - I titoli da tenere d'occhio a Wall Street	26/04
EE.UU. - Valores a seguir en Wall Street	26/04
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV	26/04
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV	26/04
News Highlights : Top Company News of the Day - Friday at 1 AM ET	26/04
News Highlights : Top Company News of the Day - Thursday at 11 PM ET	26/04
News Highlights : Top Company News of the Day - Thursday at 9 PM ET	26/04
News Highlights : Top Company News of the Day - Thursday at 5 PM ET	25/04
News Highlights : Top Company News of the Day - Thursday at 7 PM ET	25/04
Gilead Sciences Q1 Tops Estimates, Updates Outlook	25/04
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges	25/04
(GILD) GILEAD SCIENCES Forecasts Fiscal Year 2024 EPS Range $3.45 - $3.85	25/04
Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.69B, vs. Street Est of $6.348B	25/04
Gilead: Q1 Earnings Snapshot	25/04
Gilead Sciences Announces First Quarter 2024 Financial Results	25/04
Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Gilead posts quarterly loss, revenue rises 5%	25/04
Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2024	25/04

Aucun résultat pour cette recherche